Dogan, I. Et Al. 2023. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression. Scientific Reports , vol.13, no.1 .

Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & AYDINER, A., (2023). Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression. Scientific Reports , vol.13, no.1.

Dogan, Izzet Et Al. "Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression," Scientific Reports , vol.13, no.1, 2023

Dogan, Izzet Et Al. "Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression." Scientific Reports , vol.13, no.1, 2023

Dogan, I. Et Al. (2023) . "Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression." Scientific Reports , vol.13, no.1.

@article{article, author={Izzet Dogan Et Al. }, title={Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression}, journal={Scientific Reports}, year=2023}